Hydroxychloroquine, COVID-19 and the rheumatologist’s clinical responsibility
Hydroxychloroquine moved from a familiar rheumatology drug to a global focal point almost overnight when COVID-19 dominated clinical debate. The title alone captures the tension: a long-established therapy, a new infectious disease, and a specialty asked to provide steadiness when public attention surged ahead of evidence. In that setting, the rheumatologist’s role extends beyond prescribing. It includes pharmacovigilance, dose discipline, toxicity recognition, and the obligation to keep uncertainty visible when the public conversation becomes impatient.
The phrase festina lente — make haste slowly — fits the moment. Rheumatologists work with medications whose benefits and risks are rarely decided by headlines, and hydroxychloroquine is no exception. In routine rheumatologic care, the drug has a defined place because clinicians understand how to balance symptom control against ocular, cardiac, and other safety concerns. During the pandemic, that clinical memory became a form of professional ballast. It offered a counterweight to pressure from outside the specialty, where a drug with known uses in autoimmune disease was repeatedly pulled into a broader, more urgent search for antiviral answers.
One sentence can capture the bedside consequence: a familiar drug can become a clinical hazard when its context changes faster than the evidence.
That reality places rheumatologists at the intersection of two competing duties. On one side sits the responsibility to care for patients with chronic inflammatory disease who may already depend on hydroxychloroquine as part of a long-term regimen. On the other sits the need to protect patients from indiscriminate use, supply disruption, and avoidable toxicity when the drug is framed as a solution to a public health emergency. The specialty is uniquely positioned to explain that a medication’s value does not travel intact from one indication to another. A treatment can be standard in lupus or related rheumatic disease and still be unproven, inappropriate, or unsafe when repurposed for a viral illness.
That distinction matters at the level of individual decision-making. Patients do not experience drug controversies as abstract debates; they experience them as questions about access, dose changes, side effects, and whether a familiar medication is still worth continuing. Rheumatologists therefore become translators between evidence and anxiety. They must answer not only whether hydroxychloroquine has a role in COVID-19, but also whether existing patients should continue therapy, how to manage interruptions, and how to interpret new claims without overreacting to preliminary signals. This is less glamorous than a breakthrough announcement, but it is the work that prevents confusion from becoming harm.
A second sentence, equally direct: when a drug is politicized, stewardship becomes part of treatment.
The article’s emphasis on the rheumatologist signals a broader professional obligation. Specialty knowledge matters most when a medication is pulled into a crisis beyond its usual borders. Rheumatologists understand cumulative exposure, chronic toxicity, and the practical consequences of long-term treatment far better than the public debate does. They are also trained to think in risk-benefit terms rather than in slogans. That mindset is especially important for hydroxychloroquine, where safe use depends on appropriate patient selection, dose awareness, and ongoing monitoring rather than on enthusiasm alone.
In the COVID-19 era, that kind of judgment carried added weight because fear and hope often outran data. A repurposed drug can become a symbol before it becomes a therapy. Once that happens, clinicians are forced to separate what is biologically plausible from what is clinically established. Hydroxychloroquine has long been embedded in autoimmune care; its appearance in pandemic discourse did not erase that history, but it did require specialists to defend the boundaries of evidence-based use. The rheumatologist, in that sense, functions as both prescriber and custodian of therapeutic context.
The title also implies a wider lesson for specialty medicine. When a medication is thrust into a new disease state, the clinicians who know it best are often the ones best equipped to prevent overreach. They know where the drug belongs, where it does not, and what safety signals deserve immediate attention. They are also the most credible voices for patients who need continuity rather than speculation. In the case of hydroxychloroquine, that meant preserving access for established rheumatic disease indications while resisting the temptation to equate familiarity with proof.
For publication readers, the key issue is not whether hydroxychloroquine should be discussed in the context of COVID-19; it is how that discussion is conducted. The article frames rheumatology as a specialty that must keep clinical reasoning intact when public demand is pulling in the opposite direction. That role is not limited to the pandemic. It is a model for how specialty medicine should respond whenever an established drug is recast as an urgent answer to a new problem before the evidence has caught up.